Earnings Call · Q4 FY2022·2023-02-21

Q4 22EPS -100.00%*·Rev n/aQ3 22EPS +60.00%·Rev n/aQ2 22EPS 0.00%·Rev n/aQ1 22EPS +28.57%·Rev n/a⚠ consensus missing

AbCellera Biologics Inc. ABCL

Tryn Stimart — Chief Legal Officer

Carl Hansen — Chief Executive Officer

Andrew Booth — Executive, likely Chief Financial Officer or similar

−7.3%1d on move date−5.3% vs SPY3d−11.3%5d−12.1%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ABCL calls or request research access.

More ABCL calls Browse calls Request research access